

Title (en)

INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

Title (de)

INHIBITORVERBINDUNGEN DER PHOSPHODIESTERASE TYP 10A

Title (fr)

COMPOSÉS INHIBITEURS DE LA PHOSPHODIESTÉRASE DE TYPE 10A

Publication

**EP 2885299 B1 20170405 (EN)**

Application

**EP 13750071 A 20130816**

Priority

- US 201261684290 P 20120817
- EP 2013067122 W 20130816

Abstract (en)

[origin: US2014051695A1] The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof where in formula I the variables R1, R2, R3, R4 and R5 are as defined in the claims and where X is C-R6 or N, Y is C-R7 or N, where R6 and R7 are, inter alia, hydrogen, halogen, alkoxy, haloalkoxy and the like. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

IPC 8 full level

**C07D 471/04** (2006.01); **A61K 31/4745** (2006.01); **A61P 35/00** (2006.01)

CPC (source: CN EP KR US)

**A61K 31/4745** (2013.01 - KR); **A61P 3/04** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/18** (2017.12 - EP);  
**A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 25/30** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP);  
**C07D 471/04** (2013.01 - EP KR US); **C07D 471/14** (2013.01 - EP KR US); **C07D 487/04** (2013.01 - CN EP KR US)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

**US 2014051695 A1 20140220; US 9464085 B2 20161011;** AR 092167 A1 20150325; AU 2013304043 A1 20150205;  
BR 112015003236 A2 20170704; CA 2879485 A1 20140220; CL 2015000370 A1 20151002; CN 104684912 A 20150603;  
CR 20150082 A 20150525; DO P2015000029 A 20150315; EC SP15010205 A 20160129; EP 2885299 A1 20150624; EP 2885299 B1 20170405;  
HK 1211284 A1 20160520; IL 236946 A0 20150331; IN 337DEN2015 A 20150612; JP 2015524833 A 20150827; KR 20150042798 A 20150421;  
MX 2015002000 A 20151009; PE 20151069 A1 20150829; PH 12015500348 A1 20150420; RU 2015109135 A 20161010;  
SG 11201501111Y A 20150330; TW 201412742 A 20140401; UY 34980 A 20140331; WO 2014027078 A1 20140220

DOCDB simple family (application)

**US 201313968242 A 20130815;** AR P130102932 A 20130816; AU 2013304043 A 20130816; BR 112015003236 A 20130816;  
CA 2879485 A 20130816; CL 2015000370 A 20150216; CN 201380043926 A 20130816; CR 20150082 A 20150219;  
DO 2015000029 A 20150216; EC PI201510205 A 20150317; EP 13750071 A 20130816; EP 2013067122 W 20130816;  
HK 15111990 A 20151204; IL 23694615 A 20150127; IN 337DEN2015 A 20150114; JP 2015526996 A 20130816; KR 20157004416 A 20130816;  
MX 2015002000 A 20130816; PE 2015000204 A 20130816; PH 12015500348 A 20150217; RU 2015109135 A 20130816;  
SG 11201501111Y A 20130816; TW 102129554 A 20130816; UY 34980 A 20130815